Trial Profile

Phase 3 Efficacy and Safety Study of ACC007 Combined with 3TC+TDF in the Treatment of HIV/AIDS

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ainuovirine (Primary) ; Efavirenz (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary)
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Aidea Pharmaceutical

Most Recent Events

20 Oct 2024 Results pooled from (Nos. ChiCTR1800018022 and ChiCTR1800019041), assessing the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV, published in the Chinese Medical Journal.
30 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com